A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Prucalopride (MOTEGRITY)

Serotonin-4 Receptor Agonist class · 16 generic manufacturers · 32 ANDAs filed at FDA.

First FDA approval2018-12-14
Generic availableYes · 16 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$103.9M in CY2024 Part D spend145K claims · 43K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.705/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.728
Across all dosage forms in distribution.
Highest NADAC
$0.757
Range is tight.
Plans with PA
2 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Prucalopride used for?

Prucalopride is a Serotonin-4 Receptor Agonist medication tracked in Medicare Part D.

Is there a generic for Prucalopride?

Yes. 32 ANDAs filed at FDA, 16 generic manufacturers currently shipping.

How much does my plan pay for Prucalopride?

Across 329 Part D plans, Prucalopride averages $0.728/unit (NADAC). Lowest available: $0.705/unit. Highest in distribution: $0.757/unit.

Is Prucalopride on the FDA shortage list?

No. Prucalopride is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.